Clinical Treatment Studies
Clinical studies in genomics and individualized medicine help us understand how diseases develop and progress. We use this knowledge to develop better diagnostic tools and more effective therapies to improve patient care.
The Center for Individualized Medicine currently has four open clinical studies enrolling patients who meet certain eligibility criteria.
Pharmacogenomics: Right Protocol
The Right Drug, Right Dose, Right Time – Using Genomic Data to Individualize Treatment (RIGHT) protocol tests the concept that DNA sequence information can be coupled to the electronic medical record (EMR) for use in health care. The study is designed to integrate prescription drug-related genetic information in the EMR and make it readily available for health care providers to access and use when prescribing certain drugs.
Genetic variants play a role in how an individual responds to certain prescription drugs. Knowledge about these genetic variants can be used by health care providers to determine which drug is best for you and at what dose. Thus, this information can result in the right drug, at the right dose, at the right time – dramatically improving drug efficacy and safety.
Breast cancer: beauty study
The Breast Cancer Genome-Guided Therapy (BEAUTY) study is designed to help us better understand why standard chemotherapy eradicates breast cancer in some women but fails in others.
The long-term goal of the BEAUTY study is to enable individualized treatment for women with breast cancer by using the genetic information found in blood samples and tumor biopsies to predict the most effective therapies.
Prostate cancer: promote study
The Prostate Cancer Medically Optimized Genome-Enhanced Therapy (PROMOTE) study uses genetic clues to identify an individualized treatment approach for men with castration-resistant prostate cancer.
A better understanding of the genetic characteristics of each tumor helps predict which treatments will be more effective and less toxic for individual patients.
Cardiovascular disease: TAILOR-PCI study
The Tailored Antiplatelet Initiation to Lessen Outcomes Due to Decreased Clopidogrel Response After Percutaneous Coronary Intervention (TAILOR-PCI) study uses genetic information to find the best medication for patients who undergo coronary angioplasty, also known as percutaneous coronary intervention.
Up to 30 percent of patients receiving angioplasty have a genetic variant thought to interfere with their ability to metabolize standard antiplatelet medications. Alternative drugs exist, and this study investigates whether or not physicians should prescribe medication based on genotype.